CWA Asset Management Group’s Regeneron Pharmaceuticals REGN Stock Holding History

CWA Asset Management Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.01M	Sell	1,623 -48	-3%	-$32.7K	0.03%	392
2026 Q1	$1.29M	Sell	1,671 -128	-7%	-$98K	0.04%	345
2025 Q4	$1.39M	Buy	1,799 +184	+11%	+$125K	0.05%	304
2025 Q3	$908K	Buy	1,615 +185	+13%	+$105K	0.03%	372
2025 Q2	$751K	Buy	+1,430	New	+$798K	0.03%	380
2024 Q4	–	Sell	-283	Closed	-$298K	–	609
2024 Q3	$298K	Buy	+283	New	+$315K	0.02%	478
2024 Q1	$231K	Buy	+240	New	+$228K	0.01%	481

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Vest Financial Mclean, Virginia $9.52B AUM 31.6% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

CWA Asset Management Group's REGN Position: Q2 2026 in Review

CWA Asset Management Group reduced its Regeneron Pharmaceuticals (REGN) stake by 2.9% in Q2 2026, selling an estimated $32.7K and leaving 1,623 shares worth $1.01M. The position accounts for 0.03% of the portfolio, ranked #392.

CWA Asset Management Group first reported a position in REGN in Q1 2024 and has held it in 7 quarters since. The position peaked at $1.39M in Q4 2025. 334 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

CWA Asset Management Group held 1,623 shares of Regeneron Pharmaceuticals worth $1.01M as of Q2 2026.
CWA Asset Management Group sold 48 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $32.7K.
Regeneron Pharmaceuticals made up 0.03% of CWA Asset Management Group's portfolio in Q2 2026, its #392 holding.
CWA Asset Management Group first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
CWA Asset Management Group's Regeneron Pharmaceuticals position peaked at $1.39M in Q4 2025.
334 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on CWA Asset Management Group's 13F filing for Q2 2026, filed 14 Jul 2026.